Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-01
2008-04-01
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S368000, C514S369000, C514S373000, C548S302700, C548S207000, C548S154000, C548S183000
Reexamination Certificate
active
10522697
ABSTRACT:
New cycloalkanedione derivatives that are serotonin (5-hydroxytriptamine, 5-HT) 5-HT1Areceptor subtype agonists and, consequently, they are useful in the treatment of pathological states for which an agonist of these receptors is indicated.They are particularly useful as neuroprotective agents, of special interest in the treatment and prophylaxis of cerebral damage produced by traumatic or ischemic stroke.In general terms, said cycloalkanedione derivatives correspond to formula I:
REFERENCES:
patent: 4055410 (1977-10-01), Cheng
patent: 5137901 (1992-08-01), Junge et al.
patent: 6919360 (2005-07-01), Scherling et al.
patent: 0352613 (1994-04-01), None
patent: 1674103 (2006-06-01), None
patent: 2052829 (1994-04-01), None
patent: 2052829 (1994-07-01), None
patent: 2082727 (1996-03-01), None
patent: 2094690 (1997-01-01), None
patent: 2109190 (1998-01-01), None
patent: 2129370 (1999-06-01), None
patent: 2154605 (2001-04-01), None
patent: 2199086 (2004-02-01), None
patent: 2238015 (2005-08-01), None
patent: WO 9606846 (1996-03-01), None
patent: WO 9735860 (1997-10-01), None
patent: WO 9915527 (1999-04-01), None
patent: WO 9929687 (1999-06-01), None
patent: WO 03029250 (2003-04-01), None
patent: WO 2004014915 (2004-02-01), None
patent: WO 2005075480 (2005-08-01), None
patent: WO 2006069993 (2006-07-01), None
International Preliminary Examination Report for PCT Application No. PCT/ES2003/000394.
Ambrossio, E. et al., [3H]prazosin binding to central nervous system regions of male and female rats, Neurosci. Lett. 49(1-2):193-197 (1984).
Titeler, M. et al.,Selectivity of serotonergic drugs for multiple brain serotonin receptors: Role of [3H]-4-bromo-2,5-dimethoxylphenylisopropylamine( [3H]DOB),A 5-HT2agonist radioligand, Biochem. Pharmacol. 36(19):3265-3271 (1987).
Wong, D.T. et al.,Specific [3H]LY278584 binding to 5-HT3recognition sites in rat cerebral cortex, Eur. J. Pharmacol. 166(1):107-110 (1989).
Clark, R.D. et al.,1,90ALkano-Bridged 2,3,4,5-Tetrahydro-1H-3-benzazepines with affinity for the a2-adrenoceptor and the 5-HT1areceptor, J. Med. Chem. 33(2):633-641 (1990).
Grossman, C.J. et al.,Development of a radioligand binding assay for 5-HT4receptors in guinea-pig and rat brain, Br. J. Pharmacol. 109:618-624 (1993).
De Vry, J.,5-HTIA receptor agonists: recent developments and controversial issues, Psychopharmacology 121(1):1-16 (1995).
Koh, J.Y. et al.,Potentiated necrosis of cultured cortical neurons by neurotrophins, Science 268(5210):573-575 (1995).
Koroshetz, W.J. and Moskowitz, M.A.,Emerging treatments for stroke in humans, Trends Pharmacol. Sci. 17(6):227-33 (1996).
Lopez-Rodriguez, M.L. et al.,Novel benzimidazole-4-carboxylic acid derivatives as potent and selective 5-HT3receptor ligands, Bioorg. Med. Chem. Lett.6(11): 1195-1198 (1996).
Lopez-Rodriguez, M.L. et al.,Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxphenyl)piperazin-1-yl]methyl]-1,3-dioxoperhydroimidazo[1,5-alpha]pyridine: a selective 5-HT1Areceptor agonist, J. Med. Chem. 39(22):4439-4450 (1996).
Lopez-Rodriguez, M.L. et al.,2-[4-(o-Methoxyphenyl)piperazin-1-ylmethyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine as a new selective 5-HT1Areceptor ligand, Bioorg. Med. Chem. Lett. 6(6):689-694 (1996).
Matsuyama, S. et al.,Regulation of glutamate release via NMDA and 5-HT1Areceptors in guinea pig dentate gyrus, Brain Res. 728(2):175-180 (1996).
Lopez-Rodriguez, M.L. et al.,Comparative receptor mapping of serotoninergic 5-HT3and 5-HT4binding sites, J. Comput.-Aided Mol. Des. 11(6):589-599 (1997).
Lopez-Rodriguez, M.L. et al.,Synthesis and structure-activity relationships of a new model of arylpiperazines. 2. Three-dimensional quantitative structure-activity relationships of hydantoin-phenylpiperazine derivatives with affinity for 5-HT1A and alpha 1 receptors. A comparison of CoMFA models, J. Med. Chem. 40(11):1648-1656 (1997).
Lopez-Rodriguez, M.L. et al.,Synthesis and structure-activity relationships of a new model of arylpiperazines. 3.1 2-[omega-(4-arylpiperazin-1-yl)alkyl]perhydropyrrolo-[1,2-c]imidazoles and—perhydroimidazo[1,5-a]pyridines: study of the influence of the terminal amide fragment on 5-HT1A affinity/selectivity, J. Med. Chem. 40(16):2653-2656 (1997).
Aguirre, N. et al.,MDMA(‘Ecstacy’)enhances5-HT1areceptor density and 8-OH-DPAT-induced hypothermia: Blockade by drugs preventing 5-hydroxytryptamine depletion, Eur. J. Pharmacol. 346(2-3):181-188 (1998).
Beneytez, M.E. et al.,Preclinical pharmacology of B-20991, a 5-HT1Areceptor agonist with anxiolytic activity, Eur. J. Pharmacol. 344:127-135(1998).
Lopez-Rodriguez, M.L. et al.,1-[ω-(4-Arylpiperazin-1-yl)alkyl]3-diphenylmethylene-2,5-pyrrolidinediones as 5-HT1Areceptor ligands: Study of the steric requirements of the terminal amide fragment on 5-HT1Aaffinity/selectivity, Bioorg. Med. Chem. Lett. 8:581-586 (1998).
Nonaka, S. et al.,Chronic lithium treatment robustly protects neurons in the central nervous system against excitoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx, Proc. Nat'l. Acad. Sci. USA 95(5):2642-2647 (1998).
Suchanek, B. et al.,The 5-HT1Areceptor agonist BAY ×3702 prevents staurosporine-induced apoptosis, Eur. J. Pharmacol. 355(1):95-101 (1998).
Ahlemeyer B. et al.,The 5-HT1Areceptor agonist Bay ×3702 inhibits apoptosis induced by serum deprivation in cultured neurons, Eur. J. Pharmacol. 370(2):211-216 (1999).
Justicia, C. and Planas, A.M.,Transforming growth factor-αacting at the epidermal growth factor receptor reduces infarct volume after permanent middle cerebral artery occlusion in rats, J. Cereb. Blood Flow Metab. 19(2):128-132 (1999).
Lopez-Rodriguez, M.L. et al.,Benzimidazole derivatives. 1. Synthesis and structure-activity relationships of new benzimidazole-4-carboxamides and carboxylates as potent and selective 5-HT4receptor antagonists, Bioorg. Med. Chem. 7:2271-2281 (1999).
Lopez-Rodriguez, M.L. et al.,Benzimidazole derivatives. 2. Synthesis and structure-activity relationships of new azabicyclic benzimidazole-4-carboxylic acid derivatives with affinity for serotoninergic 5-HT3receptors, J. Med. Chem. 42:5020-5028(1999).
Lopez-Rodriguez, M.L. et al.,Design and synthesis of 2-[4-[4-((m--(ethylsulfonamido)phenyl)piperazin-1-yl]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole(EF-7412)using neural networks. A selective derivative with mixed 5-HT1A/D2antagonist properties, Bioorg. Med. Chem. Lett. 9:1679-1682(1999).
Lopez-Rodriguez, M.L. et al.,Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene)-2,5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2,5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1Aaffinity/selectivity, J. Med. Chem. 42(1):36-49 (1999).
Lopez-Rodriguez, M.L. et al.,Synthesis of new(benzimidazolyl)piperazines with affinity for the 5-HT1Areceptor via Pd(0)amination of bromobenzimidazoles, Bioorg. Med. Chem. Lett. 9:2339-2342, 1999.
Galter, D. et al.,Sequential activation of the 5-HT1Aserotonin receptor and TrkB induces the serotonergic neuronal phenotype, Mol. Cell. Neurosci. 15(5):446-455 (2000).
Lopez-Rodiguiez, M.L. et al.,First pharmacophoric hypothesis for 5-HT7antagonism, Bioorg. Med. Chem. Lett. 10:1097-1100(2000).
Lopez-Rodriguez, M.L. et al.,Pd(0)Amination of benzimidazoles as an efficient method towards new(benzimidazolyl)piperazines with high affinity for the 5-HT1Areceptor, Tetrahedron 56:3245-3253 (2000).
Schaper, C. et al.,Stimulation of 5-HT1Areceptors reduces apoptosis after transient forebrain ischemia in the rat, Brain Res. 883(1): 41-50 (2000).
Torup, L. et al.,Neuroprotective effect of 8-OH-DPAT in global cerebral ischemia assessed by stereological cell counting, Eur. J. Pharmacol. 395(2):137-141 (2000).
Kline, A.E. et al.,The selective 5-HT1Areceptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats, Neuroscience 106(3) 547-555 (2001).
Lopez-Rodriguez, M.L. et al.,Computational mod
Benhamú Salama Bellinda
Del Río Zambrana Joaquin
Delgado Wallace Mercedes
Frechilla Manso Diana
Fuentes Cubero José Ángel
Anderson Rebecca
Harness Dickey & Pierce PLC
Keane J. Timothy
Nolan Jason M
Schwarz Pharma S.L.
LandOfFree
Cycloalkanedione derivatives, method for the production... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cycloalkanedione derivatives, method for the production..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cycloalkanedione derivatives, method for the production... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3945225